<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00398502</url>
  </required_header>
  <id_info>
    <org_study_id>3200A3-105</org_study_id>
    <nct_id>NCT00398502</nct_id>
  </id_info>
  <brief_title>Comparisons Of The Bioavailability And Pharmacodynamics Of Various Formulations Of MOA-728 In Subjects On Methadone</brief_title>
  <official_title>A Randomized, Open-label, 3-period Crossover Study to Determine the Relative Bioavailability of Two Oral Formulations of MOA-728 and to Compare the Pharmacodynamics of the Two Oral Formulations of MOA-728 and the Subcutaneous Formulation in Subjects on Stable Methadone Maintenance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch Health Americas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch Health Americas, Inc.</source>
  <brief_summary>
    <textblock>
      Primary: To determine the relative bioavailability of MOA-728, an investigational drug,&#xD;
      administered orally in both the capsule and tablet formulations to methadone maintenance&#xD;
      subjects.Secondary: To assess the pharmacodynamic effect of MOA-728 administered both orally&#xD;
      and subcutaneously to methadone maintenance subjects using the oral-cecal transit time.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics and Pharmacodynamics</measure>
  </primary_outcome>
  <condition>Metahdone-maintenance Subjects</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MOA-728</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Men or nonlactating and nonpregnant women, aged 18 to 65 years, inclusive. Women of&#xD;
             nonchildbearing potential must be surgically sterile (hysterectomy, oophorectomy,&#xD;
             and/or tubal ligation) or postmenopausal for ³1 year. Women of childbearing potential&#xD;
             must be using an acceptable nonhormonal method of contraception (intrauterine device&#xD;
             [IUD], diaphragm, or condom with spermicidal jelly or foam, or abstinence) for a&#xD;
             period of at least 1 month before and after dose administration. All women must have&#xD;
             negative pregnancy test results within 48 hours before the start of the first test&#xD;
             article administration.&#xD;
&#xD;
          -  Body mass index in the range of 18 to 35 kg/m² and body weight ≥50 kg.&#xD;
&#xD;
          -  Healthy as determined by the investigator on the basis of medical history, physical&#xD;
             examination, clinical laboratory test results, vital signs, and 12-lead&#xD;
             electrocardiogram (ECG).&#xD;
&#xD;
          -  Subjects with positive results for HBsAg, and/or HCV antibodies may be enrolled if&#xD;
             their bilirubin and serum albumin values are within normal limits and their liver&#xD;
             function tests are within 1.2 times the upper limit of the normal range.&#xD;
&#xD;
          -  A history of methadone treatment for at least 1 month before day -1 and have a&#xD;
             positive drug test for methadone.&#xD;
&#xD;
          -  No concomitant medication with the exception of stable doses of anxiolytic agents,&#xD;
             antidepressants, Seroquel, occasional sleep medications, and drugs or supplements&#xD;
             required to enhance or maintain regulation of bowel movements (must be stopped for the&#xD;
             72 hours before the first dose of test article administration in each period).&#xD;
&#xD;
          -  Must have a high probability for compliance with and completion of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeff Cohn</last_name>
    <role>Study Director</role>
    <affiliation>Bausch Health Americas, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 9, 2006</study_first_submitted>
  <study_first_submitted_qc>November 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2006</study_first_posted>
  <last_update_submitted>November 21, 2019</last_update_submitted>
  <last_update_submitted_qc>November 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2019</last_update_posted>
  <responsible_party>
    <name_title>Jeff Cohn</name_title>
    <organization>Salix Pharmaceuticals</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

